Research Advance of CXCR4 Inhibitors in the Treatment of Acute Myeloid Leukemia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1355-1359, 2021.
Article
en Zh
| WPRIM
| ID: wpr-888566
Biblioteca responsable:
WPRO
ABSTRACT
CXCL12/CXCR4 axis composed of chemokine CXCL12 and its specific ligand CXCR4 can regulate and control the adhesion of leukemia cells to protective bone marrow niche, promote cell survival, and resist apoptosis induced by signal transduction inhibitors and chemotherapeutic drugs. Therefore, CXCL12 /CXCR4 axis has become a new target for the treatment of acute myeloid leukemia. At present, CXCR4 inhibitors that have been developed are in different clinical trials, showing good anti-leukemia effect. In this review, the research advance of CXCR4 inhibitors in the treatment of acute myeloid leukemia is summarized briefly.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Médula Ósea
/
Leucemia Mieloide Aguda
/
Transducción de Señal
/
Apoptosis
/
Receptores CXCR4
/
Quimiocina CXCL12
/
Antineoplásicos
Límite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2021
Tipo del documento:
Article